Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug
By Josh Beckerman
Biomea Fusion shares fell 61% to $4.40 after hours as the company said the Food and Drug Administration placed a full clinical hold on Phase I/II clinical trials of diabetes drug BMF-219.
The FDA cited deficiencies based on the level of possible drug-induced hepatotoxicity observed in the completed dose escalation phase of one of the two studies.
"We respect the FDA's decision and agree that patient safety is paramount and our top priority" Biomea said, and it is working with the FDA "to put a plan in place as quickly as possible to ensure patient safety."
The company said results to date have supported that BMF-219 is generally well-tolerated and can restore glucose-controlled insulin production and improve glycemic control.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 06, 2024 17:14 ET (21:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks